- Positive initial data generated in the first six patients treated with TG4050 demonstrate the strong potential of this individualized immunotherapy in ovarian cancer and head and neck cancer.
o TG4050 induced robust anti-tumor cellular immune responses against multiple neoantigen targets in all evaluable patients (4/4).
o TG4050 monotherapy was also associated with the first signs of clinical activity.
- TG4050 was well tolerated, with no related Serious Adverse Events reported across the two studies to date.
- Additional patients are being enrolled, with the aim to treat up to 43 patients across the two multicenter trials (USA, UK, France).
- Further data will be released at a major oncology conference over the coming months and will provide the insight needed to prepare Phase II trials.
Webcasts tomorrow with Key Opinion Leaders on November 23, 2021, at 8:30 a.m. CET in French and at 3 p.m. CET (8:00 a.m. ET) in English (details at the end of the release).
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer